Schizophrenia Market

Oct 01, 2020

10 likes | 19 Views

In 2017, the total prevalent population of Schizophrenia in the 7MM was 5,616,463. Among 7MM, the EU5 countries occupied 22.47% of the patient pool in 2017. The market size of Schizophrenia in 7MM was USD 6,066.97 million in 2017. Increasing awareness, growing research and development, long-acting injectable antipsychotics and pipeline advancement are some of the key factors expected to drive the Schizophrenia market in the coming years. The key companies in the Schizophrenia market include Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Forum Pharmaceuticals, BioXcel Therapeutics, Avineuro Pharmaceuticals, Alkermes, Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals, H. Lundbeck A/S, GW Research, Boehringer Ingelheim, Karuna Pharmaceuticals, Takeda, SyneuRx International, Boehringer Ingelheim, Biogen, Cerevel Therapeutics/Pfizer, Concert Pharmaceuticals, Newron Pharmaceuticals, Corcept Therapeutics, Merck, and Celon Pharma. For more details, visit: https://www.delveinsight.com/report-store/schizophrenia-market

DelveInsight

Download Presentation

Schizophrenia Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D